国际肿瘤学杂志

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (12): 911-914.doi: 10.3760/cma.j.issn.1673-422X.2013.12.010

• 综述 • 上一篇    下一篇

尼妥珠单抗治疗实体瘤的研究进展

刘巧红, 王琳琳, 孙玉萍   

  1. 271000 泰安，泰山医学院研究生部（刘巧红）；山东大学附属济南市中心医院肿瘤科（王琳琳、孙玉萍）
  • 出版日期:2013-12-10 发布日期:2013-12-26
  • 通讯作者: 孙玉萍 E-mail:sunyuping@live.cn

Nimotuzumab in the treatment of solid tumors

LIU  Qiao-Hong, WANG  Lin-Lin, SUN  Yu-Ping   

  1. Postgraduate Department, Taishan Medical  University, Taian  271000, China
  • Online:2013-12-10 Published:2013-12-26
  • Contact: SUN Yu-Ping E-mail:sunyuping@live.cn
  • Supported by:

    山东省国际科技合作项目（200913）

PDF

1827

摘要： 尼妥珠单抗（泰欣生）是一种靶向表皮生长因子受体（EGFR）的人源化单克隆抗体，可特异性与EGFR胞外域结合，阻断下游信号通路而起到抗肿瘤作用。临床研究表明，尼妥珠单抗在头颈部鳞状细胞癌、鼻咽癌和胶质瘤等实体瘤中显示出良好的抗肿瘤作用，同时具有耐受性好、皮疹发生率低等优点。

关键词: 受体, 表皮生长因子, 抗体, 单克隆, 肿瘤

Abstract: imotuzumab, a humanized monoclonal antibody against epidermal growth factor receptor (EGFR) can combine with extracellular domain of EGFR and inhibit downstream signaling pathways to prevent tumor growth. Clinical researches show that nimotuzumab has significant antitumor activity in several solid tumors such as squamous cell carcinoma of the head and neck, nasopharyngeal carcinoma, malignant glioma and so on, with advantages of good tolerance and low incidence of rashes.

Key words: Receptor, epidermal growth factor, Antibodies, monoclonal, Neoplasms